Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal Adenocarcinoma By Ogkologos - February 10, 2025 780 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ESOPEC study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma December 17, 2021 Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 Load more HOT NEWS Checking in on our Mental Health TP53 Allelic State is Critical in Myelodysplastic Syndromes Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced... ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ
